Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Income towards Parent Company (2021 - 2025)

Historic Income towards Parent Company for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $79.4 million.

  • Krystal Biotech's Income towards Parent Company rose 19212.34% to $79.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.9 million, marking a year-over-year increase of 27988.2%. This contributed to the annual value of $89.2 million for FY2024, which is 71557.81% up from last year.
  • Latest data reveals that Krystal Biotech reported Income towards Parent Company of $79.4 million as of Q3 2025, which was up 19212.34% from $38.3 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Income towards Parent Company ranged from a high of $80.7 million in Q3 2023 and a low of -$50.0 million during Q1 2022
  • Its 5-year average for Income towards Parent Company is $2.3 million, with a median of -$15.6 million in 2021.
  • Per our database at Business Quant, Krystal Biotech's Income towards Parent Company crashed by 21599.42% in 2022 and then surged by 373015.02% in 2025.
  • Krystal Biotech's Income towards Parent Company (Quarter) stood at -$21.8 million in 2021, then crashed by 46.99% to -$32.1 million in 2022, then skyrocketed by 127.12% to $8.7 million in 2023, then surged by 423.62% to $45.5 million in 2024, then soared by 74.38% to $79.4 million in 2025.
  • Its Income towards Parent Company was $79.4 million in Q3 2025, compared to $38.3 million in Q2 2025 and $35.7 million in Q1 2025.